Program
lunsekimig
Also written as “Lunsekimig” and “SAR443765”.
In Sanofi's pipeline, IL13xTSLP Nanobody VHH
. Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Nasal Polyps · Dermatitis, Atopic, led by Sanofi.
Furthest: phase 3, since Sep 17, 202510 company-led studies, 6 open or runningNext primary completion: Jun 21, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 106 open or running | phase 3since Sep 17, 2025 | May 4, 2022 | Jun 21, 2027phase 2 · NCT06676319 |
- Named in Sanofi’s own pipeline as
lunsekimig
, phase 3, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 4, 2022First study: phase 1 study in AsthmaFirst studyNCT05366764 · 36 enrolled · Germany, United Kingdom
- Oct 20, 2023Phase 2 study in AsthmaNCT06102005 · 685 enrolled · United States, Argentina, Brazil and more
- Jun 6, 2024Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT06454240 · 79 enrolled · United States, Argentina, Belgium and more
- Sep 20, 2024Phase 2 study in AsthmaNCT06609239 · 900 planned · United States, Argentina, Brazil and more
- Nov 4, 2024Phase 2 study in AsthmaNCT06676319 · 556 enrolled · United States, Argentina, Belgium and more
- Jan 17, 2025Phase 2 study in Dermatitis, AtopicNCT06790121 · 150 enrolled · United States, Czechia, Japan and more
- Apr 4, 2025Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT06914908 · 71 enrolled · United States, Argentina, Belgium and more
- Sep 17, 20252 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT07190222, NCT07190209
- Aug 25, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07793409 · 1,508 planned · United States, Canada, United Kingdom
Ahead
- Jun 21, 2027Primary completion: phase 2 study in AsthmaNCT06676319
- Feb 22, 2029Primary completion: phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT06914908
- Nov 27, 2029Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07190222
- Nov 27, 2029Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07190209
TargetBeta
“IL13xTSLP Nanobody VHH”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tilrekimig | Pfizer | phase 3 | 11 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07793409Pulmonary Disease, Chronic Obstructive · United States, Canada, United Kingdom | 3 | By invitation | Jul 23, 2031 | 1,508 |
| NCT07190222Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Recruiting | Nov 27, 2029 | 942 |
| NCT07190209Pulmonary Disease, Chronic Obstructive · United States, Argentina, Belgium and more | 3 | Recruiting | Nov 27, 2029 | 942 |
| NCT06914908Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Belgium and more | 2 | Active, not recruiting | Feb 22, 2029 | 71 |
| NCT06790121Dermatitis, Atopic · United States, Czechia, Japan and more | 2 | Completed | Feb 12, 2026 | 150 |
| NCT06676319Asthma · United States, Argentina, Belgium and more | 2 | Active, not recruiting | Jun 21, 2027 | 556 |
| NCT06609239Asthma · United States, Argentina, Brazil and more | 2 | By invitation | Jan 20, 2031 | 900 |
| NCT06454240Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Belgium and more | 2 | Completed | Jan 29, 2026 | 79 |
| NCT06102005Asthma · United States, Argentina, Brazil and more | 2 | Completed | Feb 23, 2026 | 685 |
| NCT05366764Asthma · Germany, United Kingdom | 1 | Completed | Feb 24, 2023 | 36 |
How it is read
Names in the registry
- “Lunsekimig”, 8 entries
- “lunsekimig”, 1 entry
- “SAR443765”, 1 entry
Conditions, from the studies’ own filings
- Asthma, 4 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Nasal Polyps, 2 studies
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.